evidence and practice
Hypercalcaemia of malignancy: causes and management
Colin Perdue Clinical nurse specialist, specialist palliative care, Swansea Bay University Health Board, Swansea, Wales
Patients with hypercalcaemia of malignancy present with signs and symptoms of greater severity than those with hypercalcaemia associated with non-malignant causes. Signs and symptoms may be attributed mistakenly to progression of the underlying cancer or the side effects of anti-cancer treatment. Unless treated appropriately, the signs and symptoms of hypercalcaemia of malignancy will progress quickly and ultimately become life-threatening. Rehydration with intravenous fluid followed by intravenous bisphosphonate is often effective in lowering serum calcium levels. However, unless the cancer is amenable to treatment, hypercalcaemia will recur. Even when treated, hypercalcaemia of malignancy is a poor prognostic indicator, with 80% of patients dying within 12 months of the first episode.
This article aims to raise awareness of hypercalcaemia of malignancy by discussing the underlying mechanisms, the associated signs and symptoms, and the need for prompt and appropriate treatment.
Cancer Nursing Practice. doi: 10.7748/cnp.2019.e1650Peer review
This article has been subject to external double-blind peer review and has been checked for plagiarism using automated softwareCorrespondence
Perdue C (2019) Hypercalcaemia of malignancy: causes and management. Cancer Nursing Practice. doi: 10.7748/cnp.2019.e1650
Published online: 23 September 2019
Want to read more?
Subscribe for unlimited access
Try 1 month’s access for just £1 and get:
- Full access to the website and the online archive
- Bi-monthly digital edition
- RCNi Portfolio and interactive CPD quizzes
- RCNi Learning with 200+ evidence-based modules
- 10 articles a month from any other RCNi journal
Already subscribed? Log in
Alternatively, you can purchase access to this article for the next seven days. Buy now